Get the Stockscreener App
14.77
0.94%
-0.14
After Hours:
14.71
-0.06
-0.41%
Omeros Corp stock is traded at $14.77, with a volume of 772.22K.
It is down -0.94% in the last 24 hours and up +35.50% over the past month.
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
See More
Previous Close:
$14.91
Open:
$14.98
24h Volume:
772.22K
Relative Volume:
0.73
Market Cap:
$1.07B
Revenue:
-
Net Income/Loss:
$-4.81M
P/E Ratio:
-29.55
EPS:
-0.4998
Net Cash Flow:
$-122.54M
1W Performance:
+0.68%
1M Performance:
+35.50%
6M Performance:
+111.30%
1Y Performance:
+116.89%
1-Day Range:
$14.63
$15.05
1-Week Range:
$14.37
$15.32
52-Week Range:
$2.95
$17.65
Omeros Corp Stock (OMER) Company Profile
Name
Omeros Corp
Sector
Industry
Phone
206-676-5000
Address
201 ELLIOTT AVENUE WEST, SEATTLE, WA
Compare OMER vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OMER
Omeros Corp
|
14.77 | 1.08B | 0 | -4.81M | -122.54M | -0.4998 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Omeros Corp Stock (OMER) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-10-25 | Initiated | H.C. Wainwright | Buy |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
| Dec-08-22 | Downgrade | UBS | Buy → Neutral |
| Nov-08-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-08-22 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-08-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-01-21 | Downgrade | Maxim Group | Buy → Hold |
| Oct-01-21 | Downgrade | Wedbush | Neutral → Underperform |
| Sep-27-21 | Initiated | JP Morgan | Neutral |
| Feb-01-21 | Initiated | UBS | Buy |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Aug-21-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-18 | Initiated | Seaport Global Securities | Buy |
| Mar-23-18 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-05-18 | Downgrade | Needham | Buy → Hold |
| Nov-08-17 | Initiated | H.C. Wainwright | Buy |
| May-11-17 | Downgrade | Cantor Fitzgerald | Buy → Neutral |
| Mar-17-17 | Reiterated | Maxim Group | Buy |
| Mar-17-17 | Reiterated | Needham | Buy |
| Nov-16-16 | Reiterated | Wedbush | Outperform |
| Nov-10-16 | Reiterated | Needham | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Jun-03-16 | Initiated | Cantor Fitzgerald | Buy |
| Mar-02-16 | Reiterated | Needham | Buy |
| Feb-29-16 | Reiterated | Wedbush | Outperform |
| Nov-11-15 | Reiterated | Needham | Buy |
| Aug-18-15 | Reiterated | WBB Securities | Strong Buy |
| Aug-10-15 | Initiated | ROTH Capital | Buy |
View All
Omeros Corp Stock (OMER) Latest News
Omeros (NASDAQ:OMER) Stock Price Crosses Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
OMEROS CORP ($OMER) CEO 2025 Pay Revealed - Quiver Quantitative
OMER Forecast, Price Target & Analyst Ratings | OMEROS CORP (NASDAQ:OMER) - ChartMill
Executive pay, incentives and votes detailed in Omeros (NASDAQ: OMER) 2026 proxy - Stock Titan
[ARS] OMEROS CORP SEC Filing - Stock Titan
OMER stock on track for best week in nearly 4 months after receiving permanent reimbursement code for treatment - MSN
Omeros rises as Novo deal boosts Q4 earnings - MSN
OMER stock surges 5% after hours on Novo Nordisk deal windfall and drug launch optimism - MSN
Zacks Industry Outlook Highlights Phibro Animal Health, BioLife Solutions, Omeros and Brainsway - Yahoo Finance
Omeros Stock Logs Best Session Ever After HC Wainwright Doubles Target On Novo Nordisk Deal; Retail Sees Big Upside - MSN
Omeros (NASDAQ:OMER) Trading 6.3% HigherShould You Buy? - MarketBeat
Here's Why Omeros (OMER) is a Great Momentum Stock to Buy - Yahoo Finance
Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade - Yahoo Finance
Omeros (NASDAQ:OMER) Lowered to Hold Rating by Wall Street Zen - MarketBeat
how Fair Value analysis identified Omeros’ 74% biotech breakout By Investing.com - Investing.com South Africa
how Fair Value analysis identified Omeros’ 74% biotech breakout - Investing.com
Omeros Q4 2025 earnings preview - MSN
OMER Stock Price, Quote & Chart | OMEROS CORP (NASDAQ:OMER) - ChartMill
Omeros Corporation to acquire $80.5 million of its convertible senior notes due 2026 - MSN
Ingalls & Snyder (NASDAQ: OMER) holds 3.47M shares, 4.8% stake - Stock Titan
OMER (Omeros Corporation) shares rise 7.18 percent after Q4 2025 earnings sharply outperform analyst estimates.Hot Momentum Watchlist - Xã Thanh Hà
OMER Maintained by D. Boral Capital -- Price Target Remains at $36 - GuruFocus
Omeros Is Maintained at Buy by D. Boral Capital - Moomoo
D. Boral Capital Reiterates "Buy" Rating for Omeros (NASDAQ:OMER) - MarketBeat
Sagimet Biosciences (SGMT) CMO retires as company appoints successor - Stock Titan
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer - GlobeNewswire Inc.
OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment - Stocktwits
Omeros (NASDAQ:OMER) Rating Increased to Buy at Wall Street Zen - MarketBeat
Omeros CorporationCMS Assigns Permanent Reimbursement J-Code for YARTEMLEA - marketscreener.com
Omeros receives permanent J-code for TA-TMA treatment Yartemlea By Investing.com - Investing.com India
CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug) - BioSpace
Omeros (OMER) Secures Permanent J-Code for YARTEMLEA - GuruFocus
Omeros says CMS assigns permanent reimbursement J-code for YARTEMLEA - TipRanks
Omeros Corp Stock (OMER) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):